A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

NCT00297362 · clinicaltrials.gov ↗

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Galantamine hydrobromide

Sponsor

Janssen Cilag Pharmaceutica S.A.C.I., Greece